期刊文献+

阿德福韦酯致范可尼综合征 被引量:1

Fanconi's syndrome induced by adefovir dipivoxil
原文传递
导出
摘要 1例50岁女性乙型肝炎肝硬化患者于8年前开始口服拉米夫定(100 mg/d)治疗.用药1年后出现拉米夫定耐药,加用阿德福韦酯10 mg/d.联合抗病毒治疗约6年后,患者出现下肢无力且症状逐渐加重,1年内相继出现右侧季肋区疼痛伴翻身困难、下肢活动受限和左侧季肋区疼痛.实验室检查示血磷0.55 mmol/L,血钙2.13 mmol/L,血尿酸98 μmol/L,考虑为范可尼综合征(FS),停用阿德福韦酯和拉米夫定,换用替诺福韦酯(300 mg/隔日).1个月后复查,患者血磷0.65 mmol/L,血钙2.25 mmol/L,血尿酸109 μmol/L;尿 pH 6.00,24 h尿钾69 mmol/L、钠384 mmol/L、氯350 mmol/L;骨密度检查示骨质疏松.明确阿德福韦酯相关FS的诊断,加用骨化三醇(0.25 μg/d)治疗.3个月后,患者双下肢无力症状明显好转,停用替诺福韦酯改用恩替卡韦(0.5 mg/d)治疗.停用阿德福韦酯半年后患者双下肢无力消失,两季肋区疼痛明显减轻,可耐受中等体力活动.血磷、钙、尿酸水平均恢复正常,尿电解质排出量明显减少. A 50-year-old female patient with hepatitis B cirrhosis received oral lamivudine(100 mg/d) 8 years ago. Lamivudine resistance appeared one year after the administration. Then adefovir dipivoxil 10 mg/d was added. About 6 years after the combined antiviral treatments,weakness of lower limbs appeared and gradually worsened. At following one year,the patient successively presented with right hypochondrium pain accompanied by difficulty in turning over,limited movement of the lower extremities, and left hypochondrium pain. Laboratory tests showed serum phosphorus 0.55 mmol/L,serum calcium 2.13 mmol/L,and serum uric acid 98 mol/L. Fanconi syndrome(FS)was considered. Adefovir dipivoxil and lamivudine were discontinued and changed to tenofovir disoproxil(300 mg every other day). After one month of treatment,laboratory tests showed serum phosphorus 0.65 mmol/L,serum calcium 2.25 mmol/L, serum uric acid 109 mol/L,urine pH 6.00,24 hours urine potassium 69 mmol/L,urine sodium 384 mmol/L, and urine chlorine 350 mmol/L. Bone mineral density examination showed osteoporosis. Adefovir dipivoxil-related FS was diagnosed and calcitriol(0.25 g/d)was added. Three months later,weakness of bilateral lower extremities was improved markedly. Tenofovir disoproxil was discontinued and changed to entecavir (0.5 mg/d). Six months after discontinuation of adefovir dipivoxil,weakness of bilateral lower extremities subsided,right hypochondrium pain alleviated,and moderate physical activity could be tolerated,serum phosphorus,calcium,and uric acid levels returned to normal,and urine electrolyte output was obviously reduced.
作者 宋昱 卢雅 杨重琴 康璇 王琦 申慧琴 Song Yu;Lu Ya;Yang Xueqin;Kang Xuan;Wang Qi;Shen Huiqin(Department of Gastroenterology ,the Second Affiliated Hospital of Shanxi Medical University,Taiyuan 030000, Chin)
出处 《药物不良反应杂志》 CSCD 2018年第2期140-141,共2页 Adverse Drug Reactions Journal
关键词 核苷酸类 范可尼综合征 乙型肝炎 Nucleotides Fanconi Syndrome Hepatitis B
  • 相关文献

参考文献2

二级参考文献86

  • 1李世军,章海涛.低磷血症[J].肾脏病与透析肾移植杂志,2006,15(5):457-462. 被引量:21
  • 2Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B[J]. Hepatology, 2009, 49(5 Suppl) : S1 85 -95.
  • 3Baker R. Kidney dysfunction: a safety update on adefovir (preveon) [J]. BETA, 1998, 9-10.
  • 4Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial[ J ]. JAMA, 1999, 282 (24) : 2305 -2312.
  • 5Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial [ J ]. AIDS, 2001, 15(13) : 1695-1700.
  • 6Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study [ J ]. Lancet, 2001, 358 (9283) :718-723.
  • 7Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controUed studies[J]. Kidney Int, 2004, 66(3) : 1153-1158.
  • 8Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J]. N Engl J Med, 2003, 348(9) : 808-816.
  • 94th DWE. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil [ J ]. J Antimicrob Chemother, 2007, 59 (5) : 827-832.
  • 10Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of he- patitis B e antigen-positive chronic hepatitis B[ J ]. Hepatology, 2008, 48 (3) : 750-758.

共引文献59

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部